aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results, Beats Estimates By $0.05 EPS

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings results on Friday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05, FiscalAI reports.

aTyr Pharma Stock Down 10.0%

Shares of NASDAQ ATYR traded down $0.06 during midday trading on Friday, reaching $0.50. 3,515,249 shares of the company were exchanged, compared to its average volume of 1,909,190. The stock’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.81. The stock has a market cap of $49.42 million, a P/E ratio of -0.64 and a beta of 0.66. aTyr Pharma has a one year low of $0.40 and a one year high of $7.29.

Wall Street Analysts Forecast Growth

ATYR has been the subject of several research reports. Jefferies Financial Group restated a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Wall Street Zen cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $25.67.

Institutional Trading of aTyr Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma during the second quarter worth $28,000. ADAR1 Capital Management LLC grew its stake in shares of aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after buying an additional 13,385 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of aTyr Pharma during the second quarter worth $49,000. Virtu Financial LLC bought a new stake in shares of aTyr Pharma during the fourth quarter worth $62,000. Finally, Prudential Financial Inc. bought a new stake in shares of aTyr Pharma during the second quarter worth $63,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.